Eton Pharmaceuticals, Inc.
ETON
$17.29
-$0.17-0.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 108.60% | 116.95% | 59.26% | 46.90% | -24.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 108.60% | 116.95% | 59.26% | 46.90% | -24.36% |
| Cost of Revenue | 68.13% | 150.79% | 40.40% | 53.22% | 48.94% |
| Gross Profit | 133.40% | 96.94% | 78.40% | 43.13% | -41.89% |
| SG&A Expenses | 73.26% | 77.85% | 37.74% | 21.96% | 19.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.85% | 102.51% | 13.94% | 29.55% | 48.00% |
| Operating Income | 90.87% | 41.25% | 152.38% | 192.88% | -175.59% |
| Income Before Tax | 15.67% | -84.71% | 74.56% | 186.53% | -165.52% |
| Income Tax Expenses | 22.22% | -- | -64.78% | -- | -- |
| Earnings from Continuing Operations | 15.00% | -93.83% | 73.49% | 208.29% | -166.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.00% | -93.83% | 73.49% | 208.29% | -166.70% |
| EBIT | 90.87% | 41.25% | 152.38% | 192.88% | -175.59% |
| EBITDA | 127.75% | 195.94% | 176.60% | 320.45% | -165.19% |
| EPS Basic | 18.56% | -85.71% | 73.86% | 207.56% | -166.25% |
| Normalized Basic EPS | 57.87% | -76.65% | 95.29% | 185.82% | -165.05% |
| EPS Diluted | 16.67% | -85.71% | 68.26% | 188.89% | -167.38% |
| Normalized Diluted EPS | 57.87% | -76.65% | 95.29% | 183.69% | -166.00% |
| Average Basic Shares Outstanding | 4.33% | 4.36% | 1.53% | 0.70% | 0.72% |
| Average Diluted Shares Outstanding | 4.33% | 4.36% | 1.53% | 3.23% | -0.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |